|
Use of rituximab to treat refractory Diamond-Blackfan anemia
Source:
Eur J Haematol. 2005 May;74(5):442-4.
Use of rituximab to treat refractory Diamond-Blackfan anemia.
Morimoto A, Kuriyama K, Tsuji K, Isoda K, Hibi S, Todo S, Sugimoto T, Imashuku S.
Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
Morimoto A, Kuriyama K, Tsuji K, Isoda K, Hibi S, Todo S, Sugimoto T, Imashuku S. Use of rituximab to treat refractory Diamond-Blackfan anemia. Eur J Haematol 2005: 74: 442-444. (c) Blackwell Munksgaard 2005.Abstract: We report here the first case with Diamond-Blackfan anemia (DBA) who responded to rituximab. The patient is an 8-yr-old Japanese girl with refractory DBA accompanied by complex congenital heart disease. She received two doses of rituximab, 375 mg/m(2)/wk. She became transfusion independent 6 months after the treatment without any serious side effect. However, after 8 months of transfusion-free period, her condition returned to the pretreatment level with recovery of peripheral B cells. Rituximab may be a successful therapy for refractory DBA where B cells play a crucial role in the pathogenesis of the severe anemia.
PMID: 15813920 [PubMed - in process]
|
You are currently accessing this Site as a guest. Please login or register by clicking Here
Linear Mode
